At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Quality-of-Life Assessment, and 3 other interventions for Advanced Adult Hepatocellular Carcinoma and 10 related conditions. Completed, enrolled 40 participants across 1 site.
Detailed Summary
This phase II trial studies how well sorafenib tosylate and yttrium Y 90 glass microspheres work in treating patients with liver cancer that cannot be removed by surgery. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Yttrium Y 90 glass microspheres use glass beads to carry radiation directly to tumor cells without harming normal cells. Giving sorafenib tosylate with yttrium Y 90 glass microspheres may be an effective treatment for liver cancer.
Study Details
Timeline
Interventions
Correlative studies
Ancillary studies
Given PO
Given PO
Given IA